Anti tubercular drug: compositions and methods

Details Anti tubercular drug: compositions and methods Anti tubercular drug: compositions and methods

2005-06-03

2010-11-30

Davis, Brian J (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S306000, C514S317000, C514S649000, C514S653000, C514S654000, C514S655000, C514S659000, C514S660000, C564S316000, C564S320000, C564S355000, C564S366000, C564S368000, C564S369000, C564S370000, C564S453000, C564S454000, C564S455000, C564S457000, C546S134000, C546S194000, C546S246000

Reexamination Certificate

active

07842729

ABSTRACT:
Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

REFERENCES:
patent: 2623878 (1952-12-01), Hans Isler et al.
patent: 2709169 (1955-05-01), Morren et al.
patent: 3176040 (1965-03-01), Wilkinson et al.
patent: 3197468 (1965-07-01), Sensi et al.
patent: 3463861 (1969-08-01), Gordon et al.
patent: 3553257 (1971-01-01), Halmos et al.
patent: 3579586 (1971-05-01), Zoja
patent: 3579587 (1971-05-01), Zoja
patent: 3629333 (1971-12-01), Boughton et al.
patent: 3682922 (1972-08-01), Klimstra et al.
patent: 3718655 (1973-02-01), Ferrer-Salat et al.
patent: 3769347 (1973-10-01), Kazan
patent: 3789073 (1974-01-01), Narayanan et al.
patent: 3829493 (1974-08-01), Butula et al.
patent: 3847991 (1974-11-01), Bernardi et al
patent: 3855300 (1974-12-01), Takahashi et al.
patent: 3876702 (1975-04-01), Petersen et al.
patent: 3878201 (1975-04-01), Tomcufcik
patent: 3931152 (1976-01-01), Tomcufcik et al.
patent: 3931157 (1976-01-01), Child et al.
patent: 3944608 (1976-03-01), Singh
patent: 3944616 (1976-03-01), Kazan
patent: 3944617 (1976-03-01), Singh
patent: 3944618 (1976-03-01), Singh
patent: 3944619 (1976-03-01), Singh
patent: 3953513 (1976-04-01), Oppici
patent: 3979457 (1976-09-01), Fujii et al.
patent: 4006234 (1977-02-01), Child et al.
patent: RE29358 (1977-08-01), Tomcufcik
patent: RE29588 (1978-03-01), Halmos et al.
patent: 4150030 (1979-04-01), Singh
patent: 4262122 (1981-04-01), Lees et al.
patent: 4450274 (1984-05-01), Park
patent: 4457931 (1984-07-01), Milani et al.
patent: 5104875 (1992-04-01), Jürgen et al.
patent: 526391 (1993-10-01), Chen et al.
patent: 5439891 (1995-08-01), Kapil et al.
patent: 5864045 (1999-01-01), Burholder et al.
patent: 5922282 (1999-07-01), Ledley
patent: 5985935 (1999-11-01), Kharazmi et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 7456222 (2008-11-01), Protopopova et al.
patent: 2002/0007524 (2002-01-01), Sorensen
patent: 2003/0069204 (2003-04-01), Inukai et al.
patent: 2003/0171330 (2003-09-01), Hotoda et al.
patent: 2003/0236225 (2003-12-01), Protopopova et al.
patent: 2004/0033986 (2004-02-01), Protopopova et al.
patent: 2004/0058964 (2004-03-01), Devadas et al.
patent: 2004/0147591 (2004-07-01), Kanie et al.
patent: 2005/0014800 (2005-01-01), Matsuoka et al.
patent: 669202 (1966-03-01), None
patent: 2409741 (2002-10-01), None
patent: 2007524 (1969-04-01), None
patent: 961317 (1964-06-01), None
patent: 1157143 (1969-07-01), None
patent: 1234349 (1971-06-01), None
patent: 2168986 (2001-06-01), None
patent: 803348 (1981-09-01), None
patent: 805605 (1981-09-01), None
patent: WO 91/10664 (1991-07-01), None
patent: WO 93/10073 (1993-05-01), None
patent: WO 94/28885 (1994-12-01), None
patent: WO 99/51213 (1999-10-01), None
patent: WO 03/068769 (2003-08-01), None
Database CAPLUS on STN, Acc. No. 1956:36204, GB 729332 (May 4, 1955) (abstract).
Database CAPLUS on STN, Acc. No. 1965:492228, Forbes et al., Intern. Congr. Chemotherapy, Proc., 3rd, Stuttgart (1964), Volume date 1963, 1, p. 174-177 (abstract).
Database CAPLUS on STN, Registry Numbers and structures of US 3,463,861 compounds (1969).
Roark, W.H. et al. “Bioisosterism in Drug Design: Identification of and Structure-Activity Relation-ships in a Series of Glycine Anilide ACAT Inhibitors,” No. 122:281435, abstract, Bioorganic & Medici-nal Chemistry, 1995 (abstract only).
Cymerman-Craig, J. et al. “Chemical Constitution and Anti-Tuberculous Activity: Part II: Bases Possessing the Diphenyl Structure,” 1955, 36, pp. 254-260.
Hausler, Herwig et al. “Ethambutol Analogues as Potential Antimycobacterial Agents.” Bioor-ganic & Medicinal Chemistry Letters, 2001, pp. 1678-1681.
Arain, T.M., et al., “Bioluminescence Screening in Vitro (Bio-Siv) Assays for High-Volume Antimycobacterial Drug Discovery,” Antimicrob. Agents Chemother., 1996, vol. 40, No. 6, pp. 1536-1541.
Barry, C.E., III, et al., “Use of Genomics and Combinatorial Chemistry in the Development of New Antimycobacterial Drugs,” Biochem. Pharmacol., 2000, vol. 59, pp. 221-231.
Bass, J.B., Jr., et al., “Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,” Am. J. Respir. Crit. Care Med., 1994, vol. 149, pp. 1359-1374.
Belanger, A.E., et al., “The EmbAB Genes of Mycobacterium Avium Encode An Arabinosyl Transferase Involved in Cell Wall Arabinan Biosynthesis that is the Target for the Antimycobacterial Drug Ethambutol,” Proc. Natl. Acad. Sci., 1996, vol. 93, pp. 11919-11924.
Brown, D.S., et al., “Merrifield, Alpha-MethoxyPhenyl (MAMP) Resin; A New Versatile Solid Support for the Synthesis of Secondary Amides,” Tetrahedron Lett., 1998, vol. 39, pp. 8533-8536.
Chan-Tack, K.M., “Antituberculosis-Drug Resistance,” correspondence in N. Engl. J. Med., 1998, vol. 339, No. 15, p. 1079.
Cole, S.T., et al., “Deciphering the Biology of Mycobacterium Tuberculosis from the Complete Genome Sequence,” Nature, 1998, vol. 393, pp. 537-544, [Erratum, Nature, 1998, vol. 396, p. 190].
Cuervo, J.H., et al., “Polyalkylamine Chemical Combinatorial Libraries,” in Peptides 1994: Proceedings of the European Peptide Symposium, Maia HSL Ed., Esom: Leiden, 1995, pp. 465-466.
Cynamon, et al., “Activities of Several Novel Oxazolidinones AgainstMycobacterium Tuberculosisin a Murine Model,” 1999, vol. 43, No. 5, pp. 1189-1191.
Deng, L., et al., “Recognition of Multiple Effects of Ethambutol on Metabolism of Mycobacterial Cell Envelope,” Antimicrob. Agents Chemother., 1995, vol. 39, No. 3, pp. 694-701.
Dye, C., et al., “Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country,” J. Am. Med. Assoc., 1999, vol. 282, No. 7, pp. 677-686.
Farmer, P., et. al., “The Dilemma of MDR-TB in the Global Era,” Int. J. Tuberc. Lung Dis., 1998, vol. 2, No. 11, pp. 869-876.
Garigipati, R.S., “Reagents for Combinatorial Organic Synthesis: Preparation and Uses of Rink-Chloride,” Tetrahedron Lett., 1997, vol. 38, No. 39, pp. 6807-6810.
Gordon, D.W., et. al., “Reductive Alkylation on a Solid Phase: Synthesis of a Piperazinedione Combinatorial Library,” Bioorg. Med. Chem. Lett., 1995, vol. 5, No. 1, pp. 47-50.
Gustafson, G.R., et. al., “Incorporation of Carbohydrates and Peptides into Large Triazine-Based Screening Libraries Using Automated Parallel Synthesis,” Tetrahedron, 1998, vol. 54, p. 4051-4065.
Häusler, H., et al., “Ethambutol Analogues as Potential Antimycobacterial Agents,” Bioorg. Med. Chem. Lett., 2001, vol. 11, pp. 1679-1681.
Lee, M.H., et. al., “Site-Specific Integration of Mycobacteriophage L5: Integration-Proficient Vectors forMycobacterium smegmatis, Mycobacterium tuberculosis, and bacilli Calmette-Guerin,” Proc. Natl. Acad. Sci. USA, 1991, vol. 88, pp. 3111-3115.
Lee, R.E., et. al., “Synthesis of the Mycobacterial Arabinose Donor β-D-Arabinofuranosyl-1-monophosphoryldecaprenol, Development of a Basic Arabinosyl-Transferase Assay, and Identification of Ethambutol as and Arabinosyl Transferase Inhibitor,” J. Am. Chem. Soc., 1995, vol. 117, pp. 11829-11832.
Liu, G., et. al., “A General Solid-Phase Syntheses Strategy for the Preparation of 2-Pyrrolidinemethanol Ligands,” J. Org. Chem., 1995, vol. 60, pp. 7712-7713.
March, J., “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,” 3rded., John Wiley and Sons, New York, p. 916.
O'Brien, R.J., “Scientific Blueprint for Tuberculosis Drug Development,” The Global Alliance for TB Drug Development, Inc., 2001.
Pablos-Mendez, A., et. al., “Global Surveillance for Antituberculosis-Drug Re

Affiliated with

Also associated with

Rating

Anti tubercular drug: compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti tubercular drug: compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti tubercular drug: compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4239202